

Part (II) Nitrogenous molecules metabolism

Amino acids metabolism

1. Protein/amino acids catabolism:

- Protein turnover
 - ◇ Normal cellular protein degradation
 - ◇ PEST sequence (rich in P, E, S, and T) target proteins for rapid degradation
 - ◇ In lysosome (ATP-independent processes): extracellular, membrane-associated and long-lived intracellular proteins.
 - ◇ ATP and Ubiquitin-tag → proteasome (abnormal and short-lived proteins in cytosol)
- Dietary protein surplus
 - ◇ Provide up to 90% metabolic energy in carnivores after meal.
 - ◇ Amino acids can not be stored.
- Starvation or diabetes mellitus
 - ◇ Protein is used as fuel
 - Kwashiorkor: results when a child is weaned onto a starchy diet poor in protein
 - Marasmus: both caloric intake and specific amino acids are deficient.
- Nitrogen balance
 - ◇ Positive: an excess of ingested over excreted, accompanies growth and pregnancy
 - ◇ Negative: output exceeds intake, may follow surgery, advanced cancer, and kwashiorkor or marasmus.

2. Amino acid catabolism:

- Amino group: $\text{NH}_4^+ \rightarrow (\text{NH}_3)_2\text{CO}$ (in mammal, urea cycle)
- C-skeleton: all enter TCA cycle



- ◇ Glucogenic a.a.
 - Degraded to pyruvate, a-ketoglutarate, succinyl-CoA, fumarate, oxaloacetate → glucose and glycogen.
- ◇ Ketogenic a.a.
 - Degraded to acetoacetyl-CoA and or acetyl-CoA (6 a.a.) → ketone bodies (acetone, acetoacetate, D-β-hydroxybutyrate).
 - Untreated diabetes: liver will produce large amounts of ketone bodies from fatty acids and ketogenic a.a.
 - Leu is an exclusively ketogenic a.a. that is common in proteins. Its degradation makes a substantial contribution to ketosis under starvation conditions.

■ Classification by biological function (glucogenic, ketogenic):

Glucogenic	Ketogenic	Glucogenic and ketogenic
Ala, Arg, Asp	Leu	Ile
Cys	Lys	Phe
Glu, Gly		Trp
His		Tyr
Met		
Pro, (Hyp)		
Ser		
Thr		
Val		

3. Amino acid degradation in human:

■ Amino group:

- ◇ Transamination (aminotransferase or transaminase; requires PLP-pyridoxal phosphate as a cofactor)
 - SALT test (alanine aminotransferase, or GPT)
 - SAST test (aspartate ..., or GOT)
- ◇ Transfer NH_4^+ to liver in the form of: Glu, Gln, Ala
 - In muscle tissue: pyruvate + NH_4^+ → alanine
 - Glucose-alanine cycle + Glucose-lactate cycle = Cori cycle
- ◇ Deamination (trans-deamination) in liver by **glutamate dehydrogenase**
 - Requires NAD^+ or NADP^+
 - Allosterically regulated (reflects energy needs):
 - ✓ Activator: GDP, ADP
 - ✓ Inhibitor: GTP, ATP
 - Acidosis and Gln processing in kidney
- ◇ N excretion: almost exclusively in liver:
 - NH_4^+ → urea (urea cycle)
 - 5 enzymatic steps (4 steps in urea cycle)
 - 2 cellular compartments involved
 - Urea → bloodstream → kidney → excreted into urine
- ◇ Urea cycle enzyme defect → ammonia intoxication
 - Carbamoyl phosphate synthetase I (hyperammonemia type I)
 - ✓ Supplement of carbamoyl glutamate (N-acetylglutamate analog)
 - Ornithine transcarbamoylase (hyperammonemia type II)
 - Argininosuccinate synthetase (citrullinemia)
 - ✓ Feeding arginine promotes N excretion
 - ✓ Feeding benzoate, phenylbutyrate (aromatic keto acids)
 - Argininosuccinate lyase (argininosuccinicaciduria)
 - ✓ Feeding arginine and benzoate
 - Arginase (hyperargininemia)
 - ✓ Low protein diet

■ C-skeleton: all enter mainstream metabolic pathway, TCA cycle.

- ◇ Cofactor for one C-transfer:
 - Biotin (transfer CO_2)
 - Tetrahydrofolate (H_4 folate) (transfer $-\text{HC}=\text{O}$, $-\text{HCOH}$, or $-\text{CH}_3$)
 - ✓ H_4 folate deficiency and pernicious anemia
 - S-adenosylmethionine (adoMet, SAM) (transfer $-\text{CH}_3$)
- ◇ BCAA (Val, Leu, and Ile)
 - Degraded in extrahepatic tissue (muscle, adipose tissue, kidney and brain)
 - Branched-chain aminotransferase
 - Branched-chain α -keto acid dehydrogenase complex
 - ✓ Maple syrup urine disease (MSUD)/branched-chain ketonuria
 - ✓ Diet restriction, branched-chain keto acids supplement.
- ◇ Phenylalanine and tyrosine
 - Phe → Tyr: phenylalanine hydroxylase and phenylketouria (PKU)
 - ✓ The artificial sweetener: aspartame
 - Tyrosine degradation
 - ✓ Homogentisate dioxygenase defect → alkaptonuria

4. Principal serum enzymes used in clinical diagnosis: (from Harper's 26th ed. Table 7.2)

Serum Enzyme	Major diagnostic use
Aminotransferases: AST, or SGOT ALT, or SGPT	Myocardial infarction Viral hepatitis
Amylase	Acute pancreatitis
Ceruloplasmin	Hepatolenticular degeneration (Wilson's disease)
Creatine kinase	Muscle disorders and myocardial infarction
γ -Glutamyl transpeptidase	Various liver diseases
Lactate dehydrogenase (isozymes)	Myocardial infarction
Lipase	Acute pancreatitis
Phosphatase, acid	Metastatic carcinoma of the prostate
Phosphatase, alkaline (isozymes)	Various bone disorders, obstructive liver diseases

Table 18-2

From Lehninger 3rd ed.

Medical condition	Approximate incidence (per 100,000 births)	Defective process	Defective enzyme	Symptoms and effects
Albinism	3	Melanin synthesis from tyrosine	Tyrosine 3-monooxygenase (tyrosinase)	Lack of pigmentation; white hair, pink skin
Alkaptonuria	0.4	Tyrosine degradation	Homogentisate 1,2-dioxygenase	Dark pigment in urine; late-developing arthritis
Argininemia	<0.5	Urea synthesis	Arginase	Mental retardation
Argininosuccinic acidemia	1.5	Urea synthesis	Argininosuccinate lyase	Vomiting, convulsions
Carbamoyl phosphate synthetase I deficiency	>0.5	Urea synthesis	Carbamoyl phosphate synthetase I	Lethargy, convulsions, early death
Homocystinuria	0.5	Methionine degradation	Cystathionine β -synthase	Faulty bone development, mental retardation
Maple syrup urine disease (branched-chain ketoaciduria)	0.4	Isoleucine, leucine, and valine degradation	Branched-chain α -keto acid dehydrogenase complex	Vomiting, convulsions, mental retardation, early death
Methylmalonic acidemia	<0.5	Conversion of propionyl-CoA to succinyl-CoA	Methylmalonyl-CoA mutase	Vomiting, convulsions, mental retardation, early death
Phenylketonuria	8	Conversion of phenylalanine to tyrosine	Phenylalanine hydroxylase	Neonatal vomiting; mental retardation

5. Classification by nutrition: essential vs. nonessential amino acid: * semi-essential.


Nutritionally essential	Nutritionally nonessential
Arginine*	Alanine
Histidine	Asparagine
Isoleucine	Aspartate
Leucine	Cysteine
Lysine	Glutamate
Methionine	Glutamine
Phenylalanine	Glycine
Threonine	Proline
Tryptophan	Serine
Valine	Tyrosine

6. Amino acid biosynthesis:


- N enters the pathway in the form of:
 - ◊ Glu (aminotransferase), Gln (amidotransferase)
- C-skeleton is derived from:
 - ◊ Glycolysis (3-phosphoglycerate/3-PG, phosphoenolpyruvate/PEP, pyruvate)
 - ◊ Citric acid cycle (α -KG, OAA)
 - ◊ Pentose phosphate pathway (Ribose 5-phosphate, erythrose 4-phosphate)

7. Amino acid biosynthesis in human:

- Essential a.a.: complex chemical structure, require multiple steps, human body has lost the ability to do the job...



- Non-essential a.a.: short biosynthetic pathways (only few steps)
 - α -ketoglutarate \rightarrow Glu, Gln, Arg, Pro
 - 3-phosphoglycerate \rightarrow Ser, Gly, Cys
 - Cys from Met (S) and Ser (C-skeleton)
 - Oxaloacetate \rightarrow Asp, Asn
 - Pyruvate \rightarrow Ala
 - Tyr from Phe (phenylalanine hydroxylase)
 - Phenylalanine hydroxylase is a **mixed-function oxygenases**, which catalyze simultaneous hydroxylation of a substrate by an oxygen atom of O_2 and reduction of the other oxygen atom to H_2O .
 - Phenylalanine hydroxylase requires a cofactor tetrahydrobiopterin.
 - Dihydrobiopterin reductase defect: PKU, L-dopa...
 - Supplementing the diet with H_4 biopterin itself is ineffective because it is unstable and does not cross the BBB.



- ◇ Hydroxyproline and hydroxylysine (in collagen): no specialized tRNA, not from dietary intake (degraded completely)
 - Derived from Pro and Lys after incorporation into peptides (post-translational modification)
 - The hydroxylases are **mixed-function oxygenases** that require substrate, molecular O₂, ascorbate, Fe²⁺, and α-ketoglutarate.
 - ✓ Pro + α-KG + O₂ (ascorbate, Fe²⁺) → Hydroly-Pro + succinate
 - ◇ **BCAA (Val, Leu, Ile)** can be formed by transamination with their corresponding α-keto acids (supplied in diet).
 - Ammonia intoxication....
 - Regulation
 - ◇ Allosteric feedback inhibition
 - End product acts as a modulator for the allosteric enzyme.
 - Simple and concerted inhibition.
 - ◇ Glutamine synthetase
 - Allosteric regulation
 - Covalent modification
8. S-adenosylmethionine (S-adoMet, SAM)
- Cofactor for methyl group transfer: activated methyl cycle
 - ◇ From ATP + Met (by methionine adenosyl transferase) (Fig 18-17)
 - Triphosphate of ATP is displaced by S from Met.
 - ✓ Similar reaction in coenzyme B₁₂ synthesis.
 - ◇ Met is regenerated by addition of a methyl group to homocysteine (by methionine synthase)
 - The 1-carbon donor: H₄ folate or methylcobalamin derived from coenzyme B₁₂.
 - The methyl group of methylcobalamin is derived from N⁵-methyl H₄ folate.
 - B₁₂ deficiency: may trap folate in N⁵-methyl form → pernicious anemia.

Molecules derived from amino acids:

9. Porphyrins (Gly + Succinyl-CoA)

- Multiple steps
 - ◇ ALA synthetase (ALAS1, drug-induced ALAS1 de-repression)
 - ◇ ALA dehydratase (Zn containing enzyme), can be inhibited by Pb (lead).
 - ◇ Degraded to linear tetrapyrrole derivative: bilirubin (jaundice).

10. Creatine (Gly + Arg + Met/S-adoMet)

- $\text{Cr} + \text{ATP} \leftrightarrow \text{CrP} + \text{ADP}$ (by creatine kinase)
 - ◇ Creatine (Cr) and phosphocreatine (PCr, or CrP)
 - ◇ Energy buffer in skeletal muscle
- Creatinine: from CrP by irreversible, nonenzymatic dehydration and loss of phosphate.
 - ◇ The 24-hour urinary excretion of creatinine is proportionate to muscle mass.

11. Glutathione (GSH), (Gly, Glu and Cys)

- As a redox buffer.
 - ◇ Maintain Cys in the reduced form (-SH).
 - ◇ Iron of heme in the ferrous (Fe^{2+}) state.
 - ◇ Serve as a reducing agent for glutaredoxin in deoxyribonucleotide synthesis. (Fig 22-37)
 - ◇ Remove toxic peroxides under aerobic conditions.
- Oxidized form: GSSG = two GSH linked by a disulfide bond.
 - ◇ $2 \text{GSH} + \text{R-O-O-H} \rightarrow \text{GSSH} + \text{H}_2\text{O} + \text{R-OH}$
 - ◇ Catalyzed by glutathione peroxidase (containing selenium, Se, in the form of selenocysteine).

12. D-amino acids

- Bacterial cell wall.
 - ◇ D-alanine and D-glutamate
 - ◇ Derived from L-isomers by racemase (PLP as coenzyme), which is the prime target for pharmaceutical agents (side-effect on other PLP-requiring enzymes)
 - L-fluoroalanine: tested as antibacterial drug
 - Cycloserine: to treat tuberculosis
- Peptide antibiotics.

13. From aromatic a.a. to many plant substances

- From Phe and Tyr
 - ◇ Tannins (單寧酸): inhibit oxidation in wines
 - ◇ Morphine: potent physiological effects
 - ◇ Flavor components: cinnamon oil, nutmeg (肉荳蔻), cloves (丁香), vanilla, and cayenne pepper (辣椒).

14. Amino acids are converted to biological amines by **decarboxylation** (PLP as a cofactor):

- From Tyr
 - ◇ Dopa, dopamine (\downarrow Parkinson's disease, \uparrow schizophrenia)
 - Dopa \rightarrow melanin
 - ◇ Dopamine \rightarrow norepinephrine (requires ascorbate, Cu^{2+})
 - ◇ Norepinephrine \rightarrow epinephrine (requires adoMet)
- From Glu
 - ◇ GABA (γ -aminobutyrate): \downarrow epileptic seizures

- GABA analogs to treat epilepsy and hypertension
- Or use inhibitors of GABA aminotransferase (GABA-degrading enzyme)
- From His
 - ◇ Histamine (allergic reaction, stimulate gastric acid)
 - Cimetidine (Tagamet): histamine receptor antagonist: structural analog of histamine, it promotes healing of duodenal ulcers by inhibiting secretion of gastric acid
- From Trp
 - ◇ Nicotinate (niacin), a precursor of NAD and NADP.
 - ◇ Serotonin: a potent vasoconstrictor and smooth muscle stimulator.
 - ◇ Serotonin → → melatonin.
- From Met and ornithine (by ornithine decarboxylase, PLP-requiring enzyme)
 - ◇ Spermine and spermidine: used in DNA packaging.
 - Required in large amounts in rapidly dividing cells.
 - African sleeping sickness (trypanosome-caused disease, 錐蟲病): ornithine decarboxylase has a much slower turnover rate in trypanosome than in human (human, fast turnover, less side-effect of enzyme inhibitor)
 - DMFO (difluoromethylornithine): suicide inhibitor or mechanism-based inhibitor.

15. From Arg

- NO (nitric oxide), gas, unstable and can not be stored.
 - ◇ Nitric oxide synthase (NOS): 4 cofactors (FMN, FAD, H₄ biopterin, Fe³⁺-heme)
 - ◇ Synthesis is stimulated by NOS with Ca²⁺-CaM.
 - ◇ Neurotransmission, blood clotting, and the control of blood pressure.



16. Summary of the biosynthesis of some important amines:

Amine	Amino acid precursor	Distinguishing features of pathways
Acetylcholine	Ser, Met	S-adoMet is methylating agent
Norepinephrine	Tyr	L-dopa is intermediate and precursor of melanins
Epinephrine	Tyr, Met	S-adoMet-dependent tyrosine aminotransferase induced by glucocorticoids
Serotonin	Trp	5-hydroxytryptophan intermediate
γ-aminobutyrate (GABA)	Glu	Decarboxylation reaction
Histamine	His	Decarboxylation reaction
Spermine	Ornithine, Met	Spermidine is intermediate
Creatine	Arg, Gly, Met	Guanidino group transferred to glycine
Purine nucleotide	<i>Gly</i> , Asp, Gln	Gly → part of the carbon skeleton
Pyrimidine nucleotide	<i>Asp</i> , Gln	Asp → part of the carbon skeleton

Nucleotide metabolism

17. Nucleotide

- Chemical structure:
 - ◇ Phosphate group (monophosphate)
 - ◇ Pentose (ribose, deoxyribose)
 - ◇ Nitrogenous base (A, G, C, U, T)
- Absorb UV light (max. ~ 260 nm)
- Polynucleotide: $NT_1 (5'-P) + NT_2 (3' \text{ OH- of ribose}) \rightarrow 3' \rightarrow 5'$ phosphodiester bond.
 - ◇ RNA is less stable as the 2'-OH functions as a nucleophile during hydrolysis of the 3',5'-phosphodiester bond.
 - ◇ Directional molecules: $5' \rightarrow 3'$.
 - 5'-end: free or phosphorylated 5'-OH
 - 3'-end: free 3'-OH



18. Nucleotide synthesis: **de novo** pathways and **salvage** pathways:

- Purine (two rings, shorter name) de novo synthesis:
 - ◇ **PRPP, Gln x 2, Gly, Formate x 2, CO₂, Asp** → inosine monophosphate (IMP)
 - ◇ IMP → AMP (GTP hydrolysis); IMP → GMP (ATP hydrolysis).
 - ◇ 1-C transfer (formate): requires H₄ folate (folic acid)
 - Deficiency of folic acid → purine deficiency state
 - Inhibition of H₄ folate formation → cancer chemotherapy.
 - e.g. azaserine, diazanorleucine, 6-mercaptopurine, and mycophenolic acid.
- Purine salvage pathway (less energy required):
 - ◇ Purine base + PRPP → Purine nucleotide + PPi (pyrophosphate) or
 - ◇ Purine nucleoside + ATP → Purine nucleotide + ADP.
- Liver is the major site of purine nucleotide biosynthesis.
- Regulation (allosteric feedback + reciprocal energy use):
 - ◇ Ribose 5-phosphate → PRPP → ... **AMP, ADP, GMP, and GDP**
 - ◇ IMP → **AMP** (GTP hydrolysis); IMP → **GMP** (ATP hydrolysis).
- Ribonucleotide vs. deoxyribonucleotide. (reduction at the level of diphosphate).
 - ◇ Requires: thioredoxin, thioredoxin reductase, and NADPH.
- Pyrimidine (one ring, longer name): orotate + PRPP → UMP → CMP
- UDP → dUDP → dUMP → dTMP (thymidylate synthase + 1 C-transfer)
 - ◇ Dihydrofolate reductase is required and it is a target for the anticancer drug **methotrexate** (competitive inhibitor).
 - ◇ Disorders of folate and vitamin B₁₂ metabolism results in deficiencies of TMP.
 - ◇ Thymidylate synthase is inhibited by **fluorouracil** and **Aminopterin** (mechanism-based inhibitor).

- Pyrimidine catabolism: $\text{NH}_4^+ \rightarrow$ urea, all soluble compound
 - ◇ Thymine $\rightarrow \rightarrow$ *β -aminoisobutyrate* (Harper 26th, p.300) \rightarrow *methylmalonylsemialdehyde* (an intermediate of Val catabolism) $\rightarrow \rightarrow$ succinyl-CoA (Lehninger 3rd, Fig 22-44).
 - Excretion of *β -aminoisobutyrate* increases in leukemia and severe x-ray radiation exposure due to increased destruction of DNA. However, many persons of Chinese or Japanese ancestry routinely excrete *β -aminoisobutyrate*.
 - ◇ Cytosine \rightarrow uracil $\rightarrow \rightarrow$ β -alanine.

- Disorders of purine catabolism. Purine is degraded to uric acid.
 - ◇ Gout
 - ◇ Lesch-Nyhan Syndrome:
 - Defect in **hypoxanthine-guanine phosphoribosyl transferase** (HPRT, HGPRTase, purine salvage enzyme)
 - ◇ Von Gierke's diseases
 - Glucose-6-phosphatase deficiency.
 - Enhanced PRPP precursor (R5P).
 - ◇ Hypouricemia
 - **Xanthine oxidase** deficiency (**allopurinol** is a competitive inhibitor)
 - ◇ **Immunodeficiency**
 - Accumulation of dGTP and dATP, which inhibit **ribonucleotide reductase** and thereby deplete cells of DNA precursors.
 - Both T cells and B cells are sparse and dysfunctional: **adenosine deaminase** deficiency. \rightarrow sterile "bubble" environment.
 - T cell deficiency but B cell normal: **purine nucleoside phosphorylase** deficiency.

- Many chemotherapeutic agents target enzymes in the nucleotide biosynthetic pathway.
 - ◇ **Cancer cells has a more active salvage pathway**
 - Compounds that inhibit glutamine amidotransferases (N donor)
 - Glutamine analogs: azaserine and acivicin.
 - **Thymidylate synthase** and **dihydrofolate reductase**: enzymes that provide the only cellular pathway for thymine synthesis.
 - **Fluorouracil** \rightarrow **FdUMP**: acts on thymidylate synthase (mechanism-based).
 - **Methotrexate**: inhibits dihydrofolate reductase (competitive inhibitor)
 - Aminopterin: inhibits dihydrofolate reductase.
 - ◇ **Allopurinol (purine analog) used in against African trypanosomiasis.**
 - Allopurinol is also an alternative substrate for orotate phosphoribosyltransferase, competes with orotic acid.

19. Review of amino acids:

Amino acid	Features
Gly	Break α -helix, to form β -turn; Triple helix in collagen; Creatine, heme/porphrin, purines.
α -alanine	L-Ala \rightarrow pyruvate (by ALT or SGPT); D-ala in bacterial wall and some antibiotics.
β -alanine	A metabolite of cysteine; Present in coenzyme A as β -alanyl dipeptides (carnosine) (in pantotheinic acid \rightarrow CoA); Product of degradation of pyrimidine (cytosine and uracil).
Cys	The thioethanolamine portion of coenzyme A ($\text{CO}_2 + \beta$ -mercaptoethylamine/Cys \rightarrow CoA); $\text{CO}_2 + \beta$ -mercaptoethylamine/Cys \rightarrow taurine \rightarrow bile salt. (the taurine that conjugates with bile acids such as taurocholic acid).
Ser	Serine protease (trypsin, chymotrypsin, elastase); catalytic mechanism: covalent catalysis; Irreversible inhibitor (di isopropyl fluoro phosphate, DIFP); Ser \rightarrow ethanolamine \rightarrow choline \rightarrow phosphatidylcholine/Lecithin choline \rightarrow acetylcholine Ser (palmitoyl-CoA) \rightarrow Sphingosine O-linked glycosylation site, phosphorylation site.
Thr	O-linked glycosylation site, phosphorylation site.
Asp	Asp protease (HIV-1 protease, inhibited by pepstatin); covalent catalysis; General acid-base catalysis (lysozyme, trypsin, chymotrypsin); Provide NH_3^+ in urea and purine (inosine) biosynthesis; Provide C-skeleton in pyrimidine ring biosynthesis.
Glu	General acid-base catalysis (lysozyme) Covalent catalysis (carboxypeptidase A) Guaithione: GSH peroxidase/Se.
Pro	Break α -helix, induce β -turn; Pro and HO-Pro in collagen (and HO-Lys): hydroxylation via oxidase and ascorbate.
Val, Leu, Ile	BCAA: contained β -oxidation; Energy source of muscle, not degraded in liver
Met	Specific cleaved by CNBr (cyanogens bromide) at C-terminus; Precursor of S-adoMet, spermine, spermidine
Arg	Trypsin cleaves the carboxyl site of Arg and Lys residues in peptide; Semi-essential a.a.; Precursor of NO, creatine
Lys	Trypsin cleaves the carboxyl site of Arg and Lys residues in peptide; Protein/Lys-NH ₃ ⁺ + ⁻ OOC-ubiquitin \rightarrow ubiquitin-dependent degradation.
Trp	Nicotinate (a precursor of NAD and NADP); Serotonin
His	Semi-essential a.a.; General acid-base catalysis: chymotrypsin; trypsin.